Chargement en cours...
IL-15 by continuous i.v. infusion to adult patients with solid tumors in a Phase I trial induced dramatic NK cell subset expansion
PURPOSE: The first-in-human clinical trial with human bolus i.v. infusion IL-15 (rhIL-15) was limited by treatment-associated toxicity. Here, we report toxicity, immunomodulation, and clinical activity of rhIL-15 administered as a 10-day continuous intravenous infusion (CIV) to patients with cancers...
Enregistré dans:
| Publié dans: | Clin Cancer Res |
|---|---|
| Auteurs principaux: | , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6697593/ https://ncbi.nlm.nih.gov/pubmed/31142503 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-3468 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|